Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 463-471

  Gao, Kun ^a   Li, Xiaoying ^a   Zhang, Li ^a   Bai, Lin ^a   Dong, Wei ^a   Gao, Kai ^a   Shi, Guiying ^a   Xia, Xianzhu ^c   Wu, Lingying ^b,d   Zhang, Lianfeng ^a,d  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^b CANCER HOSPITAL   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d Chaoyang District ^*  (China)

Author keywords

Interleukin 33; NF B; NK cells; Tumor metastasis

Indexed keywords

CD69 ANTIGEN; CD8 ANTIBODY; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 33; PROTEIN ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 33; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL STIMULATION; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSGENIC EXPRESSION;

MUS;

EID: 84878261769     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.002     Document Type: Article

References (45)

1. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
2. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
3. Sanada S., Hakuno D., Higgins L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 2007, 117:1538.
4. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'. PLoS One 2008, 3:e3331.
5. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205:339-346.
6. Carriere V., Roussel L., Ortega N., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 2007, 104:282-287.
7. Smithgall M.D., Comeau M.R., Yoon B.R., et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 2008, 20:1019-1030.
8. Bourgeois E., Van L.P., Samson M., et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 2009, 39:1046-1055.
9. Bonilla W.V., Frohlich A., Senn K., et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 2012, 335:984-989.
10. Chackerian A.A., Oldham E.R., Murphy E.E., et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 2007, 179:2551-2555.
11. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 2008, 7:827-840.
12. Humphreys N.E., Xu D., Hepworth M.R., et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 2008, 180:2443-2449.
13. Walzl G., Matthews S., Kendall S., et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med. 2001, 193:785-792.
14. Kurowska-Stolarska M., Stolarski B., Kewin P., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009, 183:6469-6477.
15. Xiangyang Z., Lutian Y., Lin Z., et al. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
16. Miller A.M., Liew F.Y. The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011, 131:179-186.
17. Aoki S., Hayakawa M., Ozaki H., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol. Cell Biochem. 2010, 335:75-81.
18. Yagami A., Orihara K., Morita H., et al. IL-33 mediates inflammatory responses in human lung tissue cells. J. Immunol. 2010, 185:5743-5750.
19. Hagemann T., Balkwill F., Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell. 2007, 12:300-301.
20. Jovanovic I., Radosavljevic G., Mitrovic M., et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur. J. Immunol. 2011, 41:1902-1912.
21. Milovanovic M., Volarevic V., Radosavljevic G., et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 2012, 52:89-99.
22. Zhiguang X., Wei C., Steven R., et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol Lett. 2010, 131:159-165.
23. Y. Shi, W. Wu, T. Wan, et al., Impact of polyclonal anti-CD3/CD28-coated magnetic bead expansion methods on T cell proliferation, differentiation and function, Int. Immunopharmacol., doi: 10.1016/j.intimp.2012.10.023.
24. Dobrzanski M.J., Reome J.B., Hylind J.C., et al. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J. Immunol. 2006, 177:8191-8201.
25. Y. Xie, L. Wang, A. Freywald, et al., A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling, Cell Mol. Immunol., doi: 10.1038/cmi.2012.37.
26. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 2007, 25:171-192.
27. H. Prado-Garcia, S. Romero-Garcia, D. Aguilar-Cazares, et al., Tumor-induced CD8+ T-cell dysfunction in lung cancer patients, Clin. Dev. Immunol, doi: 10.1155/2012/741741.
28. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 2009, 266:154-181.
29. Adam C., King S., Allgeier T., et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005, 106:338-344.
30. Langers I., Renoux V.M., Thiry M., et al. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012, 6:73-82.
31. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.
32. Smyth M.J., Hayakawa Y., Takeda K., et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer. 2002, 2:850-861.
33. Park M.H., Lee J.S., Yoon J.H. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J. Surg. Oncol. 2012, 106:386-392.
34. DiDonato J.A., Mercurio F., Karin M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
35. Hayden M.S., Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011, 21:223-244.
36. Lupino E., Ramondetti C., Piccinini M. IkappaB kinase beta is required for activation of NF-kappaB and AP-1 in CD3/CD28-stimulated primary CD4(+) T cells. J. Immunol. 2012, 188:2545-2555.
37. Muthuswamy R., Berk E., Junecko B.F., et al. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012, 72:3735-3743.
38. Goudeau B., Huetz F., Samson S., et al. IkappaBalpha/IkappaBepsilon deficiency reveals that a critical NF-kappaB dosage is required for lymphocyte survival. Proc. Natl. Acad. Sci. USA 2003, 100:15800-15805.
39. Samson S.I., Memet S., Vosshenrich C.A., et al. Combined deficiency in IkappaB alpha and IkappaB epsilon reveals a critical window of NF-kappaB activity in natural killer cell differentiation. Blood 2004, 103:4573-4580.
40. Ohto-Ozaki H., Kuroiwa K., Mato N., et al. Characterization of ST2 transgenic mice with resistance to IL-33. Eur. J. Immunol. 2010, 40:2632-2642.
41. Hayakawa H., Hayakawa M., Kume A., et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 2007, 282:26369-26380.
42. Kearley J., Buckland K.F., Mathie S.A., et al. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am. J. Respir. Crit. Care Med. 2009, 179:772-781.
43. Besnard A.G., Togbe D., Guillou N., et al. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 2011, 41:1675-1686.
44. Seltmann J., Werfel T., Wittmann M. Evidence for a regulatory loop between IFN-γ and IL-33 in skin inflammation. Exp. Dermatol. 2013, 22:102-107.
45. Ogawa H., Mukai K., Kawano Y., et al. Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-α on macrophages through the autocrine action of IL-6. Biochem. Biophys. Res. Commun. 2012, 420:114-118.